This is one in an occasional series highlighting the stories of patients who have received gene therapy for hemophilia B.
In 2023, appropriate adults with hemophilia B became eligible for treatment with gene therapy. CSL is proud to share stories of individuals who have received gene therapy, showcasing the real-world impact of this innovative treatment.
Read a patient story from Penn Medicine in Philadelphia
Read about a patient treated at Nebraska Medicine
Additionally, CSL released data that assessed hemophilia B patients receiving a gene therapy in their fourth year following treatment.
As more gene therapy treatments are developed and approved, experts recommend shared decision making as a framework for patients working with their doctors to consider complex medical decisions.
